The International Council for Harmonization of Technical Requirements for Pharmaceuticals for Human Use (ICH) E6 Guideline, specifically ICH E6(R3), is part of the ongoing GCP Renovation and represents a significant advancement in the conduct of clinical trials. The term “trial conduct” in this document includes processes from planning to reporting, including planning, initiating, performing, recording, oversight, evaluation, analysis, and reporting activities as appropriate.

Clinical trials are a fundamental part of clinical research that supports the development of new medicines or uses of existing medicines. Well-designed and conducted clinical trials help answer key questions in healthcare and drug development. Their results are essential for evidence-based healthcare decisions. Trials with inadequate design and/or poorly conducted trials may place participant safety at risk, yield inadequate or unreliable results, and are unethical. They waste resources and the efforts and time of investigators and participants.

Furthermore, the clinical research background is evolving rapidly, and the latest ICH E6(R3) guidelines are paving the way for a more digital, efficient, and patient-centric approach. Technology is no longer just an enhancement—it’s a necessity for ensuring compliance, improving data integrity, and streamlining trial operations. 

It's an internationally recognized standard that guides the design, conduct, monitoring, recording, analysis, and reporting of clinical trials to ensure that 'good' practice is adhered to and provides a clear framework for adopting technology, helping organizations improve their trial operations while meeting regulatory standards. By using technology, clinical trials can become safer, faster, and more effective, ultimately leading to better patient outcomes.

Key Steps for Implementing ICH E6(R3)

• Carry out a gap analysis that evaluates any present practices, finds development areas, sets improvements, and specifies actions for such improvements. 
• Review and revise the existing or draft any new Standard Operating Procedures in line with the ICH E6(R3) guidelines. 
• Enhance risk and data management systems to comply with updated requirements. 
• Provide organization-wide training to discuss each stakeholder's new processes and the guidelines' implementation updates.

Session Highlights:

• Attendees will get clarity on the regulatory changes, specifically the ICH E6(R3) updates, that will have a direct implication on their site operations.
• Navigating the new landscape of technologies that are transforming and potentially making site workflows more complicated.
• Discover strategic approaches to convert common industry challenges into unique competitive advantages.
• Learning how to position yourself for long-term success in the future of clinical research.

Why Should You Attend:

Staying ahead of ICH E6 (R3) has a significant impact on technology. Moreover, it’s not only enactment but a necessity for ensuring compliance, improving data integrity, and streamlining trial operations. Hence, by utilizing technology, clinical trials can become safer, faster, and more effective, ultimately leading to improved patient outcomes. In short, E6 (R3) intends to offer a shared GCP framework connecting sponsors, IRBs, investigators, and their regulators from clinical trial design through to final data analysis.

Who Should Attend:

• Site Directors
• Site feasibility
• Project Managers
• Regulatory Affairs
• Study Coordinator
• Clinical operations